From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857.
D002986:Clinical Trials as Topic / Q000592:standards; D005260:Female; D005376:Financial Management; D005471:Fluoroscopy / Q000009:adverse effects*; D006801:Humans; D007118:Immunoassay; D008297:Male; D008389:Marketing of Health Services; D011247:Pregnancy; D011358:Product Surveillance, Postmarketing; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000517:prevention & control*; D011832:Radiation Injuries / Q000209:etiology*; D012867:Skin / Q000528:radiation effects*; D014481:United States; D014486:United States Food and Drug Administration; D014492:United States Public Health Service; D016387:Women's Health
D017430:Prostate-Specific Antigen